For research purposes only. TB-500 is not licensed or approved for any human use in the United Kingdom. It is supplied strictly as a research chemical for laboratory and in vitro research purposes only. It is not intended for administration to humans or animals. All content on this page reflects scientific literature and is intended for researchers and laboratory professionals.
What Is TB-500?
TB-500 is a synthetic research peptide derived from thymosin beta-4 (TB-4), a naturally occurring 43-amino-acid protein found in virtually every mammalian cell. Thymosin beta-4 was first isolated from thymic tissue and has since been identified as one of the most abundant actin-binding proteins in the human body — present at concentrations of 100–500 µM in most cell types.
TB-500 itself represents a shorter synthetic fragment of TB-4, corresponding to the peptide's principal active region. While the two are related, they are chemically distinct: TB-4 is the full-length naturally occurring molecule; TB-500 is the research-grade synthetic analogue developed to isolate and study its core biological activity.
In laboratory settings, TB-500 is studied primarily for its role in actin regulation, cellular migration, angiogenesis, and tissue repair pathways.
The Biology: How Does TB-500 Work?
Understanding TB-500's mechanism begins with actin — a protein fundamental to cell structure and movement.
Actin Regulation and G-Actin Sequestration
The primary molecular function of thymosin beta-4 is G-actin sequestration. Inside cells, actin exists in two forms: globular (G-actin, monomeric) and filamentous (F-actin, polymerised). TB-4 binds G-actin monomers and regulates the equilibrium between these two forms, maintaining a reserve of actin that cells can rapidly mobilise when movement or repair is required.
When a signal for migration or tissue repair is received, TB-4 releases its bound actin to profilin — a co-factor that catalyses the addition of actin monomers to growing filament ends. This mechanism enables rapid cytoskeletal reorganisation: the cellular equivalent of instantly deploying a repair crew that was already on standby.
Research has shown that thymosin beta-4 stimulates keratinocyte (skin cell) migration two to three times over controls at remarkably low concentrations — as little as 10 picograms — underscoring the potency of this actin-mediated signalling pathway.
Cellular Migration
One of TB-500's most significant research findings involves its promotion of cellular migration. Studies demonstrate that the peptide accelerates the rate at which cells move into wounded areas. This applies across multiple cell types relevant to tissue repair, including fibroblasts, endothelial cells, keratinocytes, and progenitor cells.
Enhanced cellular migration is a foundational requirement for wound closure in laboratory models. Without sufficient cell movement toward a site of injury, the structural scaffolding of repair cannot be established effectively.
Angiogenesis
A particularly active area of TB-500 research involves its role in angiogenesis — the formation of new blood vessels. In vitro and animal model studies have consistently demonstrated that thymosin beta-4 upregulates vascular endothelial growth factor (VEGF) expression and promotes endothelial cell differentiation.
This is significant in research contexts because newly forming or damaged tissue in experimental models has high metabolic demands. Adequate blood supply delivers oxygen and nutrients to the repair zone — a rate-limiting factor particularly relevant in tissues with naturally poor vascularisation, such as tendons and cartilage.
Anti-Inflammatory Modulation
In laboratory models, TB-500 appears to dampen excessive inflammatory signalling without abolishing it entirely. Research in corneal tissue has demonstrated that thymosin beta-4 promotes cell migration, reduces inflammation, and suppresses apoptosis (programmed cell death) — a combination of effects with relevance for in vitro and preclinical tissue repair models.
What Does the Research Show?
Wound Healing Studies
Some of the most cited data on TB-500 comes from foundational wound-healing experiments conducted in animal models. In a study by Malinda et al., published in the Journal of Investigative Dermatology, thymosin beta-4 was assessed in full-thickness punch wound models in animal subjects. Researchers reported a 42% improvement in healing status compared to controls by day four, rising to 61% at day seven. The same research noted enhanced wound contraction and reduced scarring, attributed to decreased myofibroblast activity in healing tissue.
Separately, research findings from animal models demonstrate increased collagen deposition and enhanced angiogenesis in treated wounds, with reduced scarring observed, likely due to decreased myofibroblast numbers in healing tissue.
Cardiac Tissue Research
TB-500 has a more developed preclinical cardiac evidence base than many comparable research peptides. Animal models have explored thymosin beta-4's effects on cardiac tissue remodelling following experimentally induced injury, with results that have generated ongoing scientific interest. Some early-stage human research into thymosin beta-4 formulations has been conducted in specific clinical contexts, though these studies used different molecular formulations and are not directly applicable to TB-500 as a research compound. Results across cardiac models have been variable, and the translation of preclinical findings to human outcomes remains an active area of scientific investigation.
Neuroprotection
Preclinical research has explored TB-500 in traumatic brain injury animal models. In controlled cortical impact studies, TB-500 administration was associated with changes in contusion volume and neurotrophic factor expression, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These findings are preliminary and derived entirely from animal research. Human data in this area does not yet exist.
Corneal and Ocular Tissue
Thymosin beta-4 has been studied under the designation RGN-259 for dry eye disease in human clinical trials. These trials use a topical formulation of the full-length TB-4 molecule rather than the synthetic TB-500 fragment, and their findings are not directly transferable to TB-500. From a regulatory standpoint, TB-500 has not advanced beyond Phase 2 trials in any indication as of 2025, meaning it is not yet proven sufficient for FDA approval or equivalent — which is why its use remains experimental and confined to research settings.
TB-500 vs Thymosin Beta-4: Understanding the Distinction
A point of frequent confusion in the research literature is the interchangeable use of "TB-500" and "thymosin beta-4." They represent different molecules with different sequence lengths, domain composition, and experimental properties.
TB-4 is the full 43-amino-acid naturally occurring peptide. TB-500 is the shorter synthetic fragment corresponding to the active actin-binding region. In non-technical literature they are often used synonymously; in rigorous research contexts they are distinct compounds. When reviewing published studies, researchers should confirm which molecule was used — findings from TB-4 trials do not automatically apply to TB-500, and vice versa.
A 2024 study added further complexity by reporting that TB-500 may act as a pro-drug converted within biological systems to an active metabolite — specifically Ac-LKKTE — which showed the primary wound-healing activity rather than the parent compound. This remains an active area of investigation with implications for how the compound is characterised and studied going forward.
Regulatory and Safety Context
UK Regulatory Status
Current rules from the Medicines and Healthcare products Regulatory Agency (MHRA) do not permit the clinical or therapeutic use of these peptides outside approved studies. TB-500 is available in the UK strictly for research purposes, supplied to qualified researchers and laboratory professionals.
US Regulatory Status
TB-500 is not approved by the FDA for any use. The FDA has classified it as a Category 2 bulk substance, meaning it is not permitted for use in compounded preparations due to insufficient safety data.
WADA Status
TB-500 is prohibited under the World Anti-Doping Agency (WADA) Prohibited List, classified under S2 (Peptide Hormones, Growth Factors, Related Substances). This prohibition applies both in and out of competition. Researchers working in sport science contexts should be aware of this classification.
Safety Profile
Preclinical animal studies have shown good tolerability for thymosin beta-4, with no major toxicity identified. Limited clinical research — primarily using topical formulations of the full-length TB-4 molecule — has reported a satisfactory safety profile with no serious adverse events attributed to the compound. Long-term safety data for TB-500 as a research compound remains unavailable, as large-scale clinical trials have not been completed. Researchers should approach all experimental compounds with appropriate caution and institutional oversight.
Current Research Directions
Scientific interest in TB-500 continues to develop across several fields. Active areas of preclinical investigation include:
Tissue regeneration — soft tissue repair models examining tendon, ligament, and muscle repair at the cellular level, with the actin-binding and angiogenic mechanisms providing a mechanistically coherent basis for observed effects in laboratory settings. Researchers studying both compounds together may find our Wolverine Stack relevant for combined research applications.
Cardiac tissue modelling — post-infarction remodelling studies in animal models continue, though results have been variable and preclinical findings have not yet translated consistently to clinical outcomes.
Neuroscience — the BDNF and NGF expression findings from animal models have generated interest in neurological injury research, though this remains at an early preclinical stage.
Pro-drug metabolism — the 2024 finding regarding the Ac-LKKTE metabolite opens new questions about how TB-500's biological effects are mediated within experimental systems, with implications for how the compound is formulated and studied going forward.
Summary for Researchers
TB-500 is one of the most scientifically characterised research peptides currently available, with a mechanistic profile rooted in actin biology and a preclinical evidence base spanning wound healing, angiogenesis, cardiac tissue modelling, and neuroprotection research. Its derivation from the naturally occurring thymosin beta-4 molecule gives it a well-understood biological context within the existing scientific literature.
The current evidence base is predominantly preclinical — animal models and in vitro studies — with limited human data and no regulatory approval for therapeutic use in any jurisdiction. Researchers should engage with the primary literature directly, particularly the PubMed-indexed studies referenced throughout this article, and ensure all research is conducted within appropriate institutional and regulatory frameworks.
TB-500 is supplied by Velyx Research Ltd at >99% purity, laboratory grade, with independent third-party Certificate of Analysis from Janoshik. It is intended for in vitro laboratory research only and is not for human or animal administration.
References
Primary Research — Peer-Reviewed Studies
Malinda, K.M., Sidhu, G.S., Mani, H., Banaudha, K., Maheshwari, R.K., Goldstein, A.L., and Kleinman, H.K. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 113(3), 364–368. doi: 10.1046/j.1523-1747.1999.00708.x. PubMed PMID: 10469335
Philp, D., Badamchian, M., Scheremeta, B., Nguyen, M., Goldstein, A.L., and Kleinman, H.K. (2003). Thymosin beta4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19–24. PubMed PMID: 12581423
Eckert, M.J., et al. Thymosin beta-4 enhanced neuroprotection and functional recovery in a controlled cortical impact traumatic brain injury model. PubMed PMID: 21501058 (Note: full author list unconfirmed at time of publication — researchers should verify directly at pubmed.ncbi.nlm.nih.gov)
Zhu, J., Song, J., Yu, L., Zheng, H., Zhou, B., Weng, S., and Fu, G. (2016). Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation in patients with acute ST-segment elevation myocardial infarction: a pilot study. Cytotherapy, 18(8), 1037–1042. doi: 10.1016/j.jcyt.2016.05.006. PubMed PMID: 27288307
Wang, Y., et al. (2024). Activation of pro-resolving pathways mediates the therapeutic effects of thymosin beta-4 during Pseudomonas aeruginosa-induced keratitis. Frontiers in Immunology. doi: 10.3389/fimmu.2024.1445345. PubMed PMID: 39380984
Li, W., et al. (2024). In vitro study of thymosin beta-4 promoting transplanted fat survival by regulating adipose-derived stem cells. Aesthetic Plastic Surgery. doi: 10.1007/s00266-024-03876-w. PubMed PMID: 38409346
Sosne, G., et al. (2023). Thymosin beta-4: a potential novel adjunct treatment for bacterial keratitis. International Immunopharmacology, 118, 110104. doi: 10.1016/j.intimp.2023.110104. PubMed PMID: 37018981
Reviews and Systematic Literature
Crockford, D., Turjman, N., Allan, C., and Angel, J. (2010). Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 1194, 179–189. doi: 10.1111/j.1749-6632.2010.05492.x. PubMed PMID: 20536467
Goldstein, A.L., Hannappel, E., Sosne, G., and Kleinman, H.K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37–51. doi: 10.1517/14712598.2012.634793. PubMed PMID: 22074294
Treadwell, T., Kleinman, H.K., Crockford, D., Hardy, M.A., Guarnera, G.T., and Goldstein, A.L. (2012). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Annals of the New York Academy of Sciences, 1270, 37–44. doi: 10.1111/j.1749-6632.2012.06717.x. PubMed PMID: 23050815
Maple, K. and Monis, A. (2024). TB-500 Medical Evidence Review. Medical Anti-Ageing Associates. Available at: medicalantiaging.com
Regulatory Sources
Medicines and Healthcare products Regulatory Agency (MHRA). Human Medicines Regulations 2012. UK Government. Available at: legislation.gov.uk
World Anti-Doping Agency (WADA). (2025). 2025 Prohibited List: International Standard. Available at: wada-ama.org
U.S. Food and Drug Administration (FDA). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: fda.gov
National Institutes of Health, National Center for Biotechnology Information. (2025). PubChem Compound Summary: Fequesetide (TB-500). CID 10169788. Available at: pubchem.ncbi.nlm.nih.gov
Scientific Database
All PubMed references verified via the National Library of Medicine. Available at: pubmed.ncbi.nlm.nih.gov
Editorial note: This reference list covers the primary scientific literature informing this article. Where studies involve animal models or in vitro research, this is noted within the article text. Human clinical trial data referenced relates to thymosin beta-4 formulations and is not directly applicable to TB-500 as a research compound. The PMID 21501058 neuroprotection reference should be independently verified by the reader at PubMed before citation in any formal research context.
Velyx Research Ltd supplies research-grade peptides to qualified researchers in the United Kingdom. All products are for laboratory and research use only. Nothing on this website constitutes medical advice, and our products are not intended to diagnose, treat, cure, or prevent any disease or condition.